IL285430A - Methods and preparations for the treatment of mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis - Google Patents

Methods and preparations for the treatment of mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis

Info

Publication number
IL285430A
IL285430A IL285430A IL28543021A IL285430A IL 285430 A IL285430 A IL 285430A IL 285430 A IL285430 A IL 285430A IL 28543021 A IL28543021 A IL 28543021A IL 285430 A IL285430 A IL 285430A
Authority
IL
Israel
Prior art keywords
mast cell
duodenitis
compositions
gastroenteritis
esophagitis
Prior art date
Application number
IL285430A
Other languages
English (en)
Hebrew (he)
Original Assignee
Allakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc filed Critical Allakos Inc
Publication of IL285430A publication Critical patent/IL285430A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/062—Gastritis or peptic ulcer disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
IL285430A 2019-02-15 2021-08-08 Methods and preparations for the treatment of mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis IL285430A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806604P 2019-02-15 2019-02-15
US201962925704P 2019-10-24 2019-10-24
PCT/US2020/018405 WO2020168271A1 (en) 2019-02-15 2020-02-14 Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis

Publications (1)

Publication Number Publication Date
IL285430A true IL285430A (en) 2021-09-30

Family

ID=72044142

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285430A IL285430A (en) 2019-02-15 2021-08-08 Methods and preparations for the treatment of mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis

Country Status (12)

Country Link
US (1) US20220135673A1 (https=)
EP (1) EP3923986A4 (https=)
JP (1) JP2022520105A (https=)
KR (1) KR20210126084A (https=)
CN (1) CN113747918A (https=)
AU (1) AU2020223365A1 (https=)
BR (1) BR112021015009A2 (https=)
CA (1) CA3130072A1 (https=)
IL (1) IL285430A (https=)
MX (1) MX2021009626A (https=)
SG (1) SG11202108833QA (https=)
WO (1) WO2020168271A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3618868A4 (en) 2017-05-05 2021-02-24 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
IL270304B2 (en) * 2017-05-05 2024-07-01 Allakos Inc Methods and preparations for the treatment of inflammatory disorders in the digestive system
WO2021081411A1 (en) * 2019-10-24 2021-04-29 Allakos Inc. Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
JP2023547621A (ja) * 2020-10-22 2023-11-13 アラコス インコーポレイテッド 抗ｓｉｇｌｅｃ－８抗体製剤
CN116963775A (zh) * 2021-03-03 2023-10-27 爱乐科斯公司 抗siglec-8抗体制剂
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
IL316176A (en) * 2022-04-22 2024-12-01 Inhibrx Biosciences Inc SIGLEC-8 binding proteins and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2465873A1 (en) * 2010-12-16 2012-06-20 Deutsches Rheuma-Forschungszentrum Berlin Eosinophils as a therapeutic target
NZ720769A (en) * 2013-12-09 2022-10-28 Allakos Inc Anti-siglec-8 antibodies and methods of use thereof
IL270304B2 (en) * 2017-05-05 2024-07-01 Allakos Inc Methods and preparations for the treatment of inflammatory disorders in the digestive system

Also Published As

Publication number Publication date
WO2020168271A1 (en) 2020-08-20
JP2022520105A (ja) 2022-03-28
US20220135673A1 (en) 2022-05-05
SG11202108833QA (en) 2021-09-29
EP3923986A4 (en) 2022-10-12
AU2020223365A1 (en) 2021-08-26
EP3923986A1 (en) 2021-12-22
BR112021015009A2 (pt) 2021-10-05
CA3130072A1 (en) 2020-08-20
MX2021009626A (es) 2021-09-08
KR20210126084A (ko) 2021-10-19
CN113747918A (zh) 2021-12-03

Similar Documents

Publication Publication Date Title
IL285430A (en) Methods and preparations for the treatment of mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
GB202319838D0 (en) Player analysis using one or more neural networks
PH12020551923A1 (en) Methods and compositions for treating cancer
GB2610304B (en) Interface translation using one or more neural networks
EA201000219A1 (ru) Способ и композиция для лечения в-клеточных пролиферативных нарушений
ZA202201375B (en) Macrocyclic compounds as sting agonists and methods and uses thereof
ZA201904073B (en) Method for treating lignocellulosic biomass
IL285886A (en) Preparations and methods for the treatment of laminopathy
IL309296A (en) Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
IL289353A (en) Cell and method for resistance to transplantation process
IL285796A (en) Methods and preparations for the treatment of cancer
IL287981A (en) Preparations and methods for the treatment of t-cell exhaustion
GB2598194B (en) Anomaly characterization using one or more neural networks
GB2600868B (en) Game generation using one or more neural networks
WO2009124653A3 (de) Thienopyrimidine
IL305806A (en) Compounds and methods for the treatment of polycythemia
WO2011100642A3 (en) Method for treating hematological cancers
WO2012074725A3 (en) Immunomodulatory methods and systems for treatment and/or prevention of hypertension
WO2012061086A3 (en) Method of treating neuroendocrine tumors
HK40061238A (en) Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
EP3959199A4 (en) Compositions and methods for treating ras-mutant cancers
WO2012068319A3 (en) Method of treating hematological cancers
IL290834A (en) Preparations and methods for the treatment of extensive stage small cell lung cancer (es-sclc)
EP3788078A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC URTICARIA
PH12019501123A1 (en) Achievement-based payout schedule unlock techniques implemented in wager-based gaming networks